Galileo, ImmucorGamma’s fully automated instrument for the blood-bank industry, is now FDA approved to be marketed in the United States. Galileo gives transfusion service laboratories, blood-donor centers, and clinical laboratories the flexibility to run any test at any time. It features true continuous access, high throughput with a quick turnaround time, a broad test menu, and a bidirectional interface. It is designed to fit any medium- or high-volume laboratory’s workflow.

Continuous access allows technologists to load samples, order tests, and replenish reagents at any time without disrupting tests already in progress. Gioacchino De Chirico, president and CEO of ImmucorGamma, says, “Galileo has true continuous access performing all routine blood-bank tests including blood grouping, antibody screening, crossmatch, and antibody identification.”

Galileo automates ImmucorGamma’s Capture® solid phase assays. There are currently more than 150 Galileo installations in Europe that produce more than 1 million test results monthly.

ImmucorGamma
(800) 829-2553; www.immucor.com